Generic Line

Subscribe Today!

For over 25 years, Generic Line has been the leading resource of accurate, up-to-date news and analysis on FDA policies affecting generic drugs and drug patents.

Each monthly issue keeps you and your firm up to date on crucial regulatory, legislative and business changes, including the latest on:

  • The establishment of a biosimilars approval pathway
  • What Strategies are most successful in challenging blockbuster brands
  • The FTC's growing efforts to stop pay-for-delay agreements.

Plus in every issue you get links to key documents, such as FDA guidances, warning letters, rules, full texts of proposed legislation and more. 

Our 100% Money-Back Guarantee

There’s absolutely no risk to you. You get our 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Generic Line, you may cancel your subscription and receive a full refund. No questions asked.

So, why wait? Become a subscriber to Generic Line today. It couldn’t be easier.

Monthly, 12 issues/year, Electronic delivery.


$1,097 $847


Subscribe to Generic Line and save $250 off the regular one-year price of $1,097 — plus receive a FREE copy of our webinar CD, First Cycle Approval of ANDAs — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.